Arena Pharma (ARNA) Cash Flow Statement

Click line-items for a historical chart and %

Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	7.01M
Amortization of acquired technology and other intangibles	104K
Share-based compensation	9.26M
Gain from valuation of derivative liabilities	0
Amortization of prepaid financing costs	102K
Loss on extinguishment of debt
Loss on disposal of equipment	798K
Accounts receivable	-13.12M
Prepaid expenses and other assets	-514K
Accounts payable and accrued liabilities	8.82M
Deferred revenues	-4.93M
Deferred rent
Net cash used in operating activities
Purchases of short-term investments, available-for-sale
Purchases of land, property and equipment	-644K
Proceeds from sale of equipment
Other non-current assets	-659K
Net cash used in investing activities
Financing Activities
Principal payments on lease financing obligations
Proceeds from issuance of common stock	288K
Proceeds from issuance of preferred stock
Net cash provided by (used in) financing activities
Effect of exchange rate changes on cash	1.33M
Net increase (decrease) in cash and cash equivalents	-54.56M
Cash and cash equivalents at beginning of period	156.18M
Cash and cash equivalents at end of period	101.63M
Adjustments to reconcile net loss to net cash used in operating activities:
Accretion of note payable
Financing Activities
Payments on note payable
Adjustments to reconcile net loss to net cash used in operating activities:
Accretion of note payable
Financing Activities
Payments on note payable

Entities mentioned with ARNA

View All Entities